UK markets closed
NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
78.96 -0.04 (-0.05%) GOLD FUTURES
2,312.70 +1.70 (+0.07%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,130.52 +1,460.60 (+3.20%)
AMGN May 2024 270.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:53PM EDT. Market open.
| Previous close | 11.65 |
| Open | 11.01 |
| Bid | 11.40 |
| Ask | 12.30 |
| Strike | 270.00 |
| Expiry date | 2024-05-03 |
| Day's range | 9.38 - 11.49 |
| Contract range | N/A |
| Volume | |
| Open interest | 191 |
Investor's Business DailyAmgen Beats First-Quarter Expectations, But Shares Slide As Investors Watch Obesity Space
Amgen stock dipped late Thursday despite beating first-quarter expectations. The company is running a midstage study of its obesity drug.
PR NewswireAMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Amgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024.
ReutersAmgen investors await weight-loss drug data
(Reuters) -Amgen investors eyeing dramatic share price gains for rivals with successful obesity drugs will be focused on any updates the biotech company may provide on its own weight-loss drug candidates when it reports quarterly earnings on Thursday. Amgen has said it expects to have first-in-human results from a small, early-stage trial of experimental oral compound AMG786 before the end of June. "We are still collecting and analyzing the data," Amgen Chief Scientific Officer Jay Bradner told Reuters in an interview.
© 2024 Yahoo. All rights reserved.